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Abstract
Background: Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune
system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators
of total body irradiation (TBI) enhancement, but our ability to strategically use these toll-like receptor (TLR) agonists
to bolster the potency of T cell-based therapies for cancer remains elusive. Herein, we used TLR4 agonist LPS as a
tool to address how and when to use TLR agonists to effectively improve cancer immunotherapy.
Methods: To determine the mechanisms of how innate immune activation via lymphodepletion potentiated
antitumor T cell immunity, we utilized the pmel-1 melanoma mouse model. B16F10-bearing mice were preconditioned
with 5Gy TBI and given a tripartite ACT therapy (consisting of transferred pmel-1 CD8+ T cells, vaccination with fowlpox
encoding gp100, and IL-2) along with TLR4 agonist LPS. The timing of LPS administration and the requirement of
individual components of the tripartite therapy were evaluated based on tumor growth and the phenotype of
recovered splenocytes by flow cytometry. We also evaluated the role of non-toxic and clinically used TLR4 and TLR9
agonists—monophosphoryl lipid A (MPL) and CpG Oligodeoxynucleotide (CpG ODN), respectively— for ACT therapy.
Results: Here we report that while exogenous administration of LPS was able to enhance adoptively transferred CD8+
T cells’ tumor destruction, LPS treatment alone did not replace individual components of the tripartite ACT regimen, or
obviate TBI. Moreover, we found that sequentially administering LPS during or one day prior to ACT therapy
compromised tumor regression. In contrast, administering LPS after ACT potentiated the antitumor effectiveness of the
regimen, thereby supporting the expansion of transferred tumor-specific CD8+ T cells over host CD4+ T cells. We also
found that non-toxic TLR agonists MPL and CpG potentiated the antitumor activity of infused CD8+ T cells. Finally, TBI
was no longer needed to regress tumors in mice who were depleted of host CD4+ T cells, given a tripartite ACT
regimen and then treated with low dose LPS.
Conclusions: Collectively, our results identify how and when to administer TLR agonists to augment T cell-based
immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. Our
findings have clinical implications for the design of next generation immune-based therapies for patients with cancer.
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Background
The human digestive tract contains 100 times more
single-celled organisms than the sum total of all cells
within the body [1]. The microbiome has evolved in
symbiotic ways to play a key role in sustaining human
health, including the absorption of nutrients, mainten-
ance of mucosal integrity and the regulation of intestinal
homeostasis [2–5]. Homeostatic disruption can induce
microbial translocation, triggering a switch in the com-
mensal host-microbe relationship from mutualistic to
pathogenic [6, 7]. This phenomenon exacerbates graft-
versus-host disease, inflammatory bowel disease and
HIV/AIDS infection [8–10]. Surprisingly, the deleterious
effect of this phenomenon via chemo- and/or radiotherapy
is beneficial for T cell-based treatments for cancer; includ-
ing adoptive T cell transfer (ACT) therapy [11–14].
Lymphodepletion with chemotherapy and/or radiation
preparative regimens administered prior to adoptive
immunotherapy mediates objective clinical responses in
~50 % of patients with metastatic melanoma and has
recently shown promise in metastatic cervical cancer
[15–17]. Likewise, ACT treatment with anti-CD19
chimeric antigen receptor (CAR)-engineered T cells
mediates robust tumor immunity in preconditioned pa-
tients with hematological malignancies [18–22]. Add-
itionally, tumor mutation-specific T cells are now being
exploited for ACT therapy [23]. How lymphodepletion
augments ACT in these various clinical trials has been
elucidated in clinically relevant mouse models of
melanoma.
A non-myeloablative lymphodepleting preparative
regimen with 5Gy TBI prior to an ACT regimen can in-
duce destruction of B16F10 melanoma in mice by re-
moving cytokine sinks, depleting suppressive Treg cells,
transiently ablating myeloid derived suppressor cells
(MDSCs) and activating the innate immune system [11].
Interestingly, innate immune activation via microbial
LPS and other microbial agonists, liberated from the
radiation-injured gut, was responsible for triggering toll-
like receptor 4 (TLR4) signaling and is a mechanism
underlying the enhanced ACT effectiveness in mice [11,
24–27]. Removal of signaling components, through the
use of mice deficient in TLR4, reduced the beneficial ef-
fect of TBI [11]. Likewise, cancer patients who carry a
TLR4 loss-of-function allele relapsed more quickly after
chemotherapy than those carrying the normal TLR4 al-
lele [28]. Additional investigation revealed that increas-
ing the intensity of irradiation from 5 to 9Gy TBI, which
requires hematopoietic stem cell (HSC) support, further
enhanced treatment outcome [29]. Collectively, these
findings illuminate an important role for innate immun-
ity in augmenting T cell-based tumor immunity.
Microbes released from the radiation-injured gut con-
tain a plethora of TLR ligands besides LPS. Any of these
ligands may contribute to activating the innate immune
system. However, herein, we used TLR4 agonist LPS as a
tool to address how and when to use adjuvants to im-
prove cancer immunotherapy. We asked if TLR4 agonist
LPS could replace and/or enhance vaccines, transferred
CD8+ T cells and/or host lymphodepletion in an aggres-
sive model of melanoma. We found that activating the
innate immune system in non-irradiated mice with ex-
ogenously delivered LPS could not replicate the effect-
iveness of TBI when used in conjunction with ACT
therapy. Yet, exogenous LPS could augment the antitu-
mor activity of infused CD8+ T cells in mice receiving a
non-myeloablative, low level of irradiation (5Gy TBI).
We also found that administering LPS after, but not be-
fore or simultaneous with, ACT treatment was optimal
for potentiating the antitumor activity of infused CD8+
T cells. Additional investigation revealed that co-
administration of LPS plus antibody depletion of host
CD4+ T cells triggered robust tumor eradication. Sur-
prisingly, this combination eliminated the previous re-
quirement for TBI. LPS is not the only TLR agonist
capable of enhancing ACT. We found that the use of
MPL or CpG in similar conditions also augmented ACT.
Collectively, these findings provide insight into how
to use other TLR agonists with ACT regimens and
suggests alternative reagents to lymphodepletion that
might safely treat patients sensitive to chemotherapy/
radiotherapy.
Results
Lymphodepletion augments transferred antitumor CD8+ T
cells by activating DCs and ablating host lymphocytes
Lymphodepletion with 5Gy TBI enhances a tripartite
ACT treatment consisting of PFI (P = infusion of 1e6
pmel-1 CD8+ T cells, F = vaccination with fowlpox en-
coding hgp100 and I = high dose IL-2) in mice with
B16F10 melanoma to a greater extent than in lymphore-
plete mice (Fig. 1a). We evaluated how lymphodepletion
impacts the activation of the innate immune system and
the degree of pmel-1 CD8+ T cell engraftment vs. host
cell depletion. The improved outcomes in 5Gy TBI + PFI
treated mice compared to non-irradiated + PFI treated
mice correlated with a higher relative frequency of
donor pmel-1 CD8+ T cells in the tumor (Fig. 1b). More-
over, we found that irradiated mice had an increased
number of activated DCs expressing the co-stimulatory
molecules CD86, OX40L, ICOSL and 41BBL; likely pro-
moting the proliferation of infused CD8+ lymphocytes
(Fig. 1c). Given that 5Gy TBI decreases the cellular
density in mice over time, we evaluated the absolute
number of immune cells following TBI. We found that
increasing the intensity of lymphodepletion from 0 to
5Gy TBI was associated with a greater reduction in the
absolute number of splenic host CD4+ and CD8+ T cells
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(Fig. 1d; Day 3 CD4+ and CD8+ cells: 0Gy TBI-10.6 and
6.45e6; 5Gy TBI-0.35 and 0.56e6, respectively). Consist-
ent with previous work [11, 30], the absolute number of
activated dendritic cells in the spleen transiently in-
creased as the intensity of irradiation was increased from
0 to 5Gy TBI (Fig. 1d; Day 1 CD11b+CD11chiCD86hi
cells: 0Gy TBI-0.5e4; 5Gy TBI-13.5e4). Collectively, these
data revealed that the addition of TBI correlated with a
greater depletion of endogenous lymphocytes and activa-
tion of the innate immune system.
The antitumor activity of transferred CD8+ T cells is
compromised in MyD88 deficient mice post-irradiation
We reported that TLR4 signaling was critical for a ro-
bust antitumor response, as TLR4 knockout mice had
reduced antitumor benefits following TBI [11]. As other
a b
c d
Fig. 1 Lymphodepletion augments the antitumor activity of transferred CD8+ T cells via depleting host suppressor T cells and activating APCs. a
TBI augmented antitumor responses in mice. C57BL6 mice bearing subcutaneous B16F10 tumors established for 8 days received non-myeloablative
5Gy TBI or were not irradiated. One day later, mice received an ACT treatment regimen consisting of the adoptive transfer of 1e6 cultured tumor-
reactive pmel-1 CD8+ T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated (NT). Data (mean +/- SEM, n = 5 mice per group) are
representative of 5 independent experiments. PFI vs. 5Gy PFI, **P < .01, ANOVA. b TBI increased the engraftment of infused pmel-1 CD8+ T cells
over host CD8+ or host CD4+ T cells relative to non-irradiated mice. Ratios of transferred pmel-1 CD8+ T cells (Vβ13+Ly5.1+) relative to returning host
CD8+ and CD4+ T cells are shifted toward pmel-1 CD8+ T cells in irradiated mice. B6 mice were given 5Gy TBI or not followed by the transfer of 1e6
pmel-1 CD8+ T cells (Ly5.1+), fowlpox hgp100 vaccination and hIL-2. Splenocytes obtained 1 week after transfer were simultaneously analyzed for
infused pmel-1 CD8+ and reconstituting host cells. c TBI up-regulates costimulatory molecules on host CD11b+CD11chi dendritic cells. Splenic DCs
were isolated at 24 h from mice treated with 5Gy TBI or without. The expression of costimulatory molecules (CD86, ICOSL, OX40L and 41BBL) on
CD11chi-gated DCs were analyzed by flow cytometry and displayed in histogram form. d TBI depletes endogenous CD4+ and CD8+ T cells and
transiently promotes activation of CD11chi dendritic cells. Splenocytes were isolated from 0 and 5Gy irradiated mice 2 days after TBI. Absolute numbers
of CD4+, CD8+ and activated CD11b+CD11chiCD86hi DCs in the spleens of TBI and non-irradiated C57BL6 mice were enumerated. Data shown are
representative of 2 independent experiments. **P < .01, unpaired t-test
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innate microbes and changes in gut microbes in general,
likely triggered by TBI, were responsible for activating
the innate immune system, we sought to elucidate if glo-
bal ablation of MyD88 (a universal adapter protein used
by almost all TLRs (except TLR3) to activate transcrip-
tion factor NF-κB [31]) signaling would also impair
treatment outcome by ACT therapy in lymphodepleted
animals. To address this question, we examined the con-
sequences of a tripartite ACT therapy (PFI) in WT ver-
sus MyD88 deficient animals with or without 5Gy TBI.
Tumor destruction was significantly impaired in irradi-
ated MyD88-/- mice (P < 0.02; black diamond vs. black
circle) compared to irradiated WT mice (Fig. 2a). Con-
versely, we observed no difference between the effective-
ness of ACT tumor treatment in non-irradiated WT or
MyD88-/- mice (Fig. 2a). Additionally, we discovered that
TBI damages the integrity of the gut by pathological
score (Fig. 2b) and permitted microbial translational in
irradiated mice, as detected by LPS in the serum of irra-
diated mice 6 days after TBI (Fig. 2c). Our preliminary
work shows that LPS can be detected confidently at days
5 to 7, but not before this time point (not shown). Thus,
our data identified an essential role for MyD88 in the in-
duction and stability of antitumor CD8+ T cells in irradi-
ated mice. We surmised that microbial TLR agonist
(such as LPS and beyond) enhanced ACT tumor treat-
ment via MyD88-dependent signaling in irradiated ani-
mals only.
Administration of LPS after ACT enhances antitumor
immunity only in irradiated animals
Because microbial LPS was detected in the sera of irradi-
ated animals (Fig. 2c), we used TLR4 agonist LPS as a
tool to address how and when to use TLR agonists to
potentially improve adoptive T cell transfer cancer im-
munotherapy. We posited that administering ultrapure
LPS to non-irradiated mice would bypass the previous
need for TBI to augment ACT therapy. We first deter-
mined the highest dose of LPS that could be tolerated in
non-irradiated mice given ACT therapy. To this end, in-
creasing doses of ultrapure LPS, ranging from 0.1 to
10 μg, were administered to non-irradiated animals one
day after an ACT and PFI therapy and their tolerance
was monitored by their overall appearance and survival.
In contrast to our hypothesis, we found that even the
highest tolerable dose of LPS (5 μg) administered to
non-irradiated mice could not enhance the treatment or
their survival (Fig. 3a). Treating mice with 10 μg of LPS
was toxic to the mice with limited survival 2 days after
its administration (not shown). Collectively, these data
showed that merely increasing the dose of LPS to the
highest tolerable dose was not sufficient to improve
ACT in non-irradiated animals compared with ACT in
irradiated mice.
We next sought to determine what dose of LPS might
safely and most effectively enhance ACT treatment in
animals given 5Gy TBI. Thus, LPS doses ranging from
0.1 to 25 μg were administered to irradiated animals one
day after treatment. In contrast to our findings in non-
irradiated animals, 1 μg of LPS could significantly
a
b c
Fig. 2 TLR-MyD88 signaling triggered by TBI is critical for augmenting
the antitumor activity of transferred CD8+ T cells. Tumor bearing mice
were given tripartite ACT therapy consisting of an infusion of 1e6
transgenic pmel-1 CD8+ T cells with a TCR that recognizes the gp100
peptide on B16 tumors, a viral vaccination encoding gp100 peptide
and IL-2 cytokine support in WT versus MyD88 deficient animals with
or without 5Gy TBI. a The effectiveness of treatment was decreased in
irradiated mice genetically deficient in MyD88. WT and MyD88–/–
tumor-bearing mice were irradiated and then received ACT treatment
or were left untreated. Data (mean ± SEM; 5 mice per group) are
representative of 2 independent experiments. 5Gy PFI >WT vs. 5Gy
PFI > MyD88-/-, **P < .01, ANOVA. b TBI compromises the colon. Colon
of mice were analyzed at 3 days post-TBI and scored by a pathologist
unaware of the treatment groups. Data shown (3 mice per group)
are representative of 5 independent experiments. *P < .05, unpaired
t test. c TBI promotes translocation of gut-derived LPS. Serum from
non-irradiated and 5Gy irradiated mice were collected and analyzed
for the presence of LPS using a LAL assay 6 days after TBI. Data shown
(3 mice per group) are representative of 5 independent experiments.
*P < .05, unpaired t-test
Nelson et al. Journal for ImmunoTherapy of Cancer  (2016) 4:6 Page 4 of 14
potentiate CD8+ T cell-mediated tumor eradication in ir-
radiated animals. Likewise, doses of LPS exceeding 1 μg
of LPS improved ACT treatment (Fig. 3b) and doses
lower than 1 μg of LPS did not augment ACT treatment.
Interestingly, LPS doses that were toxic in non-
irradiated mice were well tolerated in irradiated hosts
given ACT treatment. Thus, 25 μg of LPS, a dose highly
toxic to all non-irradiated mice, was well tolerated in ir-
radiated animals (not shown). The reduced toxicity ob-
served in irradiated, but not in non-irradiated, mice
given LPS might be due to the fact that TBI ultimately
reduces (transiently) the absolute number of innate im-
mune cells triggered by LPS [32]. Collectively, our data
revealed that LPS greatly improves treatment outcome,
but only in conjunction with TBI.
LPS induces CD25 on antitumor CD8+ T cells and
supports their persistence
How exogenous LPS impacts the phenotypic signature
and proliferative capacity of infused pmel-1 CD8+ T cells
in mice given TBI remains incompletely elucidated.
Thus, we investigated how LPS influenced the expres-
sion of CD62L, CD44 and CD25 on transferred T cells
in non-irradiated and irradiated mice 5 days post-
infusion. Interestingly, LPS doubles the expression of
CD25, a receptor for IL-2, on all transferred cells, re-
gardless of therapy, but irradiation clearly enhances
CD25 expression (86 %) on infused donor pmel-1 T cells
(non-irradiated, 31 %; Fig. 4a). These data imply that in-
fused tumor-specific CD8+ T cells from irradiated mice
given LPS might have an advantage in consuming the
homeostatic cytokine IL-2 in vivo. In contrast, there
were no differences in the expression of CD62L (Fig. 4a)
and CD44 (not shown) on the transferred T cells in irra-
diated or non-irradiated mice given LPS. To investigate
how LPS impacts the in vivo proliferative capacity of the
infused pmel-1 CD8+ T cells, we treated the mice with
BrdU and determined its percent incorporation into in-
fused pmel-1 cells 3 days post-transfer. We found that
the transferred cells from irradiated mice given LPS in-
corporated significantly more BrdU than in mice re-
ceiving TBI alone (Fig. 4b). Moreover, LPS was less
effective at driving the proliferation of infused CD8+ T
cells in non-irradiated animals. These data might imply
that ablating suppressive lymphocytes with TBI while
concomitantly intensifying innate activation through
administration of a higher concentration of LPS to the
host unmasked the proliferative capacity of the trans-
ferred pmel-1 CD8+ T cells. However, additional experi-
ments will be needed to confirm this postulation. Also,
it will be insightful to know whether the expression of
receptors for IL-7, IL-15 and IL-21 on donor T cells
were up-regulated following TBI. The absolute number
of pmel-1 CD8+ T cells was also considerably elevated
in the spleen and blood of irradiated mice receiving
LPS (compared with irradiated mice not receiving LPS)
35 days after treatment (Fig. 4c). Collectively, our data
indicate that administering LPS to irradiated animals
a
b
Fig. 3 Administration of LPS enhances antitumor immunity in
irradiated but not lymphoreplete mice. a LPS does not augment
antitumor responses in non-irradiated mice. Mice bearing subcutaneous
B16F10 tumors were established for 8 days. Mice received an ACT
treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T
cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. The
next day, mice received ultra-pure LPS ranging from 0.5 to 5 μg or
left untreated. Data shown (mean ± SEM, 10 mice per group) are
representative of 2 independent experiments. PFI vs. PFI + 0.5,
1 or 5 LPS, NS, ANOVA. b LPS augments the antitumor activity of
pmel-1 CD8+ T cells in irradiated mice. Mice bearing subcutaneous
B16F10 tumors established for 8 days received 5Gy TBI. One day
after TBI, mice received an ACT treatment comprised of the adoptive
transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination
and hIL-2 or were left untreated. The next day, mice received LPS
ranging from 0.5 to 5 μg or left untreated. Data shown (mean ±
SEM, 5–10 mice per group) are representative of 2 independent
experiments. 5 Gy PFI (white circle) vs. 5Gy PFI + 0.5 LPS (white
square), NS. ANOVA. 5Gy PFI + 0.5 LPS (white square) vs. 5 Gy
PFI + 1 or 5 LPS (grey or black square), ***P < .001, ANOVA
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drives the proliferative capacity and increases the per-
sistence of transferred cells.
Infused CD8+ T cells, vaccine and IL-2 are required to
eradicate melanoma in irradiated mice treated with LPS
Because LPS bolstered the persistence of infused CD8+
T cells and mediated curative responses in irradiated
mice, we hypothesized that LPS administration might
drive tumor regression without the need for vaccination
or IL-2. To address this idea, we replaced infused
tumor-specific CD8+ T cells, vaccination via fowlpox ex-
pressing hpg100 or high dose IL-2 with LPS in irradiated
mice. Although administration of LPS reproducibly me-
diated tumor regression in irradiated mice receiving the
tripartite ACT treatment, LPS did not replace individual
components of the regimen (Fig. 5). Indeed, replacing
infused cells or vaccination with LPS in the tripartite
regimen impaired the treatment achieved in irradiated
mice given the tripartite regimen (Fig. 5b and c, respect-
ively). In contrast, replacing IL-2 with LPS was compar-
able to treatment seen in irradiated mice only given the
tripartite regimen (in other words: 5Gy PFI (Fig. 5a;
white circle) = 5Gy PF + LPS (Fig. 5d; grey diamond)),
implying that LPS might improve the capacity of trans-
ferred cells to acquire endogenous IL-2. This idea is
plausible given our finding that LPS increased CD25 ex-
pression on infused CD8+ T cells (Fig. 4a). Nonetheless,
replacing IL-2 with LPS was less effective than treatment
driven by LPS in irradiated mice receiving the entire tri-
partite regimen (5Gy, PFI + LPS; black circle)-which was
the most efficacious treatment. Collectively, we found
that LPS administration enhanced ACT therapy in irra-
diated mice but did not replace individual components
of the regimen.
LPS administration, relative to ACT therapy, impacts
treatment outcome
TLR agonists are used clinically alone or in combination
with tumor vaccines [33–37]. Although TLR agonists
plus vaccine combinations have shown success in trig-
gering T cell immune responses in patients, they have
not consistently mediated tumor regression [38]. Inter-
estingly, when testing TLR agonist combinations with
different therapeutic strategies, investigators have not
determined the optimal timing for administering TLR
agonists relative to vaccines, checkpoint modulators
and/or T cell-based therapies [39].
Although we found that administering LPS after ACT
therapy potentiates the effectiveness of the tripartite
therapy in animals (for example Fig. 3b), it remained
a b
c
Fig. 4 LPS enhances CD25 expression on transferred CD8+ T cells and improves their long-term persistence in irradiated animals. a LPS enhances
the expression of CD25, but not CD62L, on adoptively transferred pmel-1 CD8+ T cells (Ly5.1+) when analyzed on day 7 from irradiated B6 mice
given fowlpox hgp100 and hIL-2 as demonstrated by flow cytometry. b LPS enhances the initial proliferation of adoptively transferred cells as
indicated via BrdU incorporation. On day 3 post-ACT, mice were given 1 mg of BrdU and sacrificed 2 h later. Transferred cells were analyzed
for BrdU uptake (5 mice per group). c LPS increased the absolute number of transferred pmel-1 T cells in the spleen and blood of irradiated
hosts. Absolute numbers of transferred pmel-1 cells (CD8+Ly5.1+) in the spleens and blood were enumerated from Thy1.1 mice. Data shown
(mean ± SEM, 5 mice per group) are representative of 2 independent experiments. *P < .05, **P < .01, unpaired t-test
Nelson et al. Journal for ImmunoTherapy of Cancer  (2016) 4:6 Page 6 of 14
unknown whether this time-point was ideal to deliver
TLR agonists relative to T cell infusion, vaccination and
IL-2. To address this question, as depicted in Fig. 6a, we
administered LPS either one day prior, during or one
day after the tripartite ACT regimen and monitored
tumor growth in irradiated animals. Consistent with pre-
vious experiments, administering LPS after ACT poten-
tiated CD8+ T cell-mediated tumor regression (Fig. 6b).
In stark contrast, treating mice with LPS one day before
ACT treatment statistically impaired tumor growth and
mice rapidly died (Fig. 6c). Administering LPS at the
same time as ACT did not impact treatment outcome
compared to ACT treatment alone (Fig. 6d).
We next sought to explore how the timing of LPS ad-
ministration relative to the ACT regimen impacts the
engraftment of infused pmel-1 CD8+ T cells versus host
CD4+ T cells in vivo. We found that delivering LPS after
the ACT regimen increased the absolute number of
donor CD8+ T cells (Fig. 6e) to host CD4+ T cells
(Fig. 6f ) in the spleen of irradiated mice 7 days after the
treatment regimen, which likely explains why this ap-
proach effectively regresses B16F10 tumor. Conversely,
giving LPS before the regimen supported host CD4+ T
cells over infused pmel-1 CD8+ T cells (Fig. 6e and f),
which likely impaired the antitumor activity of CD8+ T
cells. If LPS was given to mice after ACT, it increased
the ratio of infused CD8+ T cells to host CD4+ T cells in
the tumor of mice (Fig. 6g). In contrast, a high ratio of
host CD4+ T cells to infused CD8+ T cells was observed
in the tumor of mice given LPS prior to the ACT
a b
c d
Fig. 5 Vaccination, bolus IL-2 and infusion of tumor-reactive lymphocytes are required to potentate ACT tumor treatment in irradiated mice given
LPS. a LPS augmented the antitumor activity of CD8+ T cells in irradiated mice given the tripartite treatment. b Removal of pmel-1 T cells; c fowlpox
hgp100 vaccine or d bolus IL-2 impaired the enhanced antitumor response mediated in irradiated mice given a tripartite therapy and LPS. One day
after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or
were left untreated. The next day, mice received 2 μg of LPS or left untreated. Data shown (mean ± SEM, 5–10 mice per group) are representative of 2
independent experiments. 5Gy (white triangle) vs. 5Gy PFI (white circle, *P < .05), 5Gy FI+ LPS (grey triangle, NS), 5Gy PI + LPS (grey square, *P < .05) or
5Gy PF + LPS (grey diamond, *P < .05), ANOVA. 5Gy PFI + LPS (black circle) vs. 5Gy PFI (white circle, *P < .05), 5Gy FI + LPS (grey triangle, ***P < .001),
5Gy PI + LPS (grey square, **P < .01) or 5Gy PF + LPS (grey diamond, *P < .05), ANOVA





Fig. 6 The timing by which LPS is administered relative to ACT therapy differentially impacts treatment outcome and regulates the innate and
adaptive immune system. a Schematic showing the time at which LPS is administered to tumor bearing mice relative to the tripartite ACT
treatment regimen. One day after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox
hgp100 vaccination and hIL-2 or were left untreated. Either on day prior (b), during (c) or one day after (d) ACT, mice received 2 μg of LPS or
were left untreated. Data shown (mean ± SEM, 5 mice/group) are representative of 4 independent experiments. 5Gy (black diamond) vs. 5Gy PFI (white
diamond, **P < .01), 5Gy PFI pre-LPS (red circle, *P < .05), 5Gy LPS during PFI (blue circle, **P < .01) or 5Gy PFI post-LPS (green circle, **P < .01), ANOVA.
5Gy PFI (white diamond) vs. 5Gy PFI pre-LPS (red circle, *P < .05), 5Gy LPS during PFI (blue circle, NS) or 5Gy PFI post-LPS (green circle, **P < .01),
ANOVA. (e–g) Splenocytes were harvested from irradiated mice on day 7 post-T cell infusion and absolute cell counts were determined by
flow cytometry. *P < .05, **P < .01, unpaired t-test. (h & i) CD11chi dendritic cells were sorted by flow cytometry from single-cell B16F10 tumor
suspensions prepared 6 days after ACT treatment from mice given LPS at different time points (as shown in scheme A). Tumor-infiltrating DCs
were co-cultured for 4 days with CFSE-labeled, negatively-isolated pmel CD8+ T cells at a 10:1 T cells: APC ratio. DCs were exposed to antigen
during in vivo fowlpox vaccination. Tumor antigen was not added to the co-culture. Representative flow cytometry plots (h) and dot plots (i)
of CFSE dilution of pmel-1 cells. ****P < .0001, **P < .01, ANOVA
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tripartite regimen. Note, our preliminary data show that
there are more host CD25highFOXP3+ CD4+ T cells and
less donor pmel-1 CD8+ T cells in irradiated mice given
LPS before PFI versus in mice given LPS after PFI
(Additional file 1 A and B). These data indicate that the
timing in which TLR agonists are used relative to ACT
can dramatically impact treatment outcome, likely by
altering the ratio of tumor-specific CD8+ T cells to
host immune cells.
Dendritic cells residing within tumors of mice treated
with LPS after a tripartite ACT regimen stimulate pmel-1
CD8+ T cell proliferation
Because LPS impaired the engraftment and antitumor
activity of infused pmel-1 CD8+ T cells, we assumed that
LPS prematurely activated host DCs and thus compro-
mised their ability to take up, process and present anti-
gen delivered via vaccination. To test this idea, we
sought to observe the ability of tumor-residing DCs
(from treatment groups in Fig. 6b, c, d) to stimulate the
division of pmel-1 CD8+ T cells. Single cell suspensions
of established melanoma from mice treated with LPS ei-
ther before, during or after ACT therapy was sorted by
flow cytometry for dendritic cells. Sorted DCs were then
co-cultured with CFSE-labeled, pmel-1 TCR transgenic
splenocytes at a 10:1 ratio of T cells: DCs. DCs isolated
from tumors of mice treated with LPS prior to or during
ACT regimen failed to robustly induce pme l-1 CD8+ T
cell division (Fig. 6h). In contrast, DCs isolated from
B16 tumors of mice treated with LPS after the tripartite
ACT regimen stimulated strong in vitro CD8+ T cell
proliferation within 4 days of co-culture (Fig. 6h). These
findings show that DCs from mice given LPS after ACT
promoted ex vivo proliferation of pmel-1 CD8+ T cells
were significant and reproducible (Fig. 6i). Collectively,
our data suggest that LPS potentiates the ability of DCs
to drive pmel-1 CD8+ T cell responses to tumors in vivo
when administered one day after the tripartite regimen.
Next, we sought to test our hypothesis that LPS bene-
ficially increases co-stimulatory molecules only if given
after PFI. We found that giving LPS to mice after ACT
only slightly increased the expression of co-stimulatory
molecules CD80 and CD86 on conventional DCs as well
as on monocytes from the spleens of mice (3 days post
ACT). Moreover, a minor increase in these molecules
was induced on APCs if LPS was given before ACT
(Additional file 1 C and D). We did not see an increase
in co-stimulatory molecules 41BBL, OX40L or ICOSL
on conventional DCs or monocytes by administering
LPS to irradiated mice (either before or after PFI). Per-
haps we did not see an increase in these particular mole-
cules because TBI itself induces them. As shown in
Fig. 1c, TBI induces these molecules, but they are lower
on the APCs from non-irradiated cohorts. Collectively,
our data imply that LPS slightly enhances DC activation,
which might contribute to improving ACT therapy.
Administration of MPL or CpG enhances antitumor
immunity in irradiated mice
Owing to its inherent toxicity, it is important to find an
alternate agonist to LPS for tumor immunotherapy in
the clinic. Moreover, some patients have TLR4 polymor-
phisms, rendering their innate immune system resistant
to microbial LPS by chemotherapy or TBI [28]. Thus,
we sought to determine whether TLR2/TLR4 monopho-
spholipid A (MPL-a detoxified version of LPS) could
also augment ACT treatment in irradiated hosts. Similar
to ultrapure LPS, we found that MPL was effective in
mediating tumor regression by the transferred cells
(Fig. 7a). Importantly, we also found that another
bacterial-derived agonist CpG-DNA (TLR9 agonist;
Fig. 7b) augmented PFI treatment in irradiated mice.
These data are important, as these agonists have been
safely used in the clinic.
Tumor eradication via ACT therapy can be achieved
without host preconditioning
We next posited that lymphodepletion with 5Gy TBI or
chemotherapeutics, which can have toxic side effects in
patients, could be bypassed in animals with established
melanoma if they were transiently depleted of host CD4
+ T cells, given a tripartite ACT therapy and then treated
with LPS. As shown in Fig. 8a, WT mice were first anti-
body depleted of CD4+ T cells prior to and during an
ACT regimen and then treated with LPS one day after
the cells were infused. Indeed, we found that the admin-
istration of LPS enhanced tumor destruction only in
non-irradiated mice that were depleted of host CD4+ T
cells (PFI + anti-CD4 + LPS > PFI + LPS or PFI + anti-
CD4; Fig. 8b). Long-term cures (>70 days) were ob-
served in these mice. Conversely, the depletion of CD4+
T cells alone or the activation of the innate immune sys-
tem with LPS alone induces weak antitumor CD8+ T cell
immune responses in non-irradiated animals with mel-
anoma (Fig. 8b).
We were curious if depleting CD4+ T cells would im-
pact the expansion of transferred CD8+ T cells. Al-
though, the ratio of donor pmel-1 CD8+ T cells to host
CD4+ T cells significantly increases when anti-CD4 anti-
body is given (Additional file 2), the number of CD8+ T
cells did not change. It is possible that transiently re-
moving host CD4+ T cells permits infused CD8+ T cells
to better interface and be activated by APCs when mice
are given LPS. Collectively, we speculate that depletion
of host CD4+ T cells (which can function and cytokine
sink or suppressors) plus LPS treatment bolster that an-
titumor properties (function and persistence) of infused
pmel-1 CD8+ T cells in non-irradiated mice. Given the
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increased interest to determine and use novel neo-
antigens to trigger effective T cell responses in patients
with cancer [23], our data offers important insights into
how and when to use TLR agonists to effectively aug-
ment T cell-based immunotherapies. Collectively, we
identified the critical determinants for mediating suc-
cessful ACT with TLR signaling and used this informa-
tion to potentiate the antitumor activity of transferred
CD8+ T cells with vaccination but without host
preconditioning.
Discussion
Lymphodepletion enhances adoptive immunotherapy via
several reported mechanisms [40]. In addition to the re-
moval of myeloid-derived suppressor cells, cytokine
sinks and Treg cells, translocation of gut microflora by
TBI impacts the outcome of adoptive immunotherapy
[11]. This intriguing finding that bacteria can promote
tumor regression is reminiscent of Coley’s work with pa-
tients treated with repeated inoculations of erysipelas
published in 1893 [41]. Yet, how to properly use bacteria
or TLR agonists to most optimally enhance vaccines,
checkpoint modulators and cellular therapy remains in-
completely explored. Herein, we used TLR4 agonist LPS
as a tool to address how and when to use TLR agonists
to effectively improve cancer immunotherapy. We asked
whether LPS could replace host lymphodepletion, vac-
cines or transferred CD8+ T cells in an aggressive model
of melanoma.
In patients with advanced metastatic melanoma, a
non-myeloablative regimen prior to infusion of tumor-
infiltrating lymphocytes and bolus IL-2 resulted in an
objective response rate of 50 % [42]. While the tolerated
doses of lymphodepletion are well established, these sys-
temic approaches are not devoid of toxicities. In mice,
we report here that lymphodepletion to 5Gy TBI corre-
lated with greater innate immune activation. Heightened
innate activation was associated with greater impairment
of the gastrointestinal tract, as evidenced by destruction
of the colon and greater microbial LPS translocation
[11]. However, we wished to find an effective and safe
way to activate the innate immune system without com-
promising the GI tract. Thus, we administered LPS to
non-irradiated mice receiving ACT. LPS could not aug-
ment ACT-mediated tumor regression in non-irradiated
mice. However, low dose LPS could improve ACT treat-
ment in mice given 5Gy TBI. Additional investigation
revealed that LPS increased the expression of CD25 on
pmel-1 CD8+ T cells infused into lymphodepleted mice.
We are particularly intrigued by the fact that LPS ro-
bustly increased CD25 on donor pmel-1 CD8+ T cells in
irradiated mice. Our new finding complements work
from our colleague Mark Rubinstein. His lab recently
published that the induction of CD25 on CD8+ T cells
via IL-12 augments the engraftment potential and anti-
tumor activity of adoptively transferred CD8+ T cells
without host lymphodepletion [43]. Mechanistically,
CD25 (i.e. the IL-2Rα) mediates IL-2 signaling and en-
hances immunotherapy. Based this new finding, we sur-
mise that it is possible that LPS induced IL-12 by APCs
in vivo. Thus, LPS-induced IL-12 possibly up-regulated
CD25 on donor CD8+ T cells and in turn increasing the
a b
Fig. 7 Administration of MPL or CpG enhances antitumor immunity in irradiated mice. Mice bearing subcutaneous B16F10 tumors established for
8 days received 5Gy TBI. One day after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells,
fowlpox hgp100 vaccination and hIL-2 or were left untreated. The next day, mice received either (a) 5 μg MPL (i.v.) or (b) 10 μg of CpG (i.t.), daily for
4 days, or left untreated. Data shown (mean ± SEM, 5–10 mice per group) are representative of 2 independent experiments. For MPL treatment: 5Gy
PFI vs. NT (*P < 0.05) or 5Gy MPL post-PFI (*P < 0.05), ANOVA. For CpG treatment: 5Gy PFI vs. NT (**P < 0.01) or 5Gy CpG post-PFI (*P < 0.05), ANOVA
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capacity of infused CD8+ T cells to consume homeo-
static available IL-2 in the host. We are now conduct-
ing follow up studies in our lab to address this
hypothesis.
Collectively, our data revealed that LPS alone is not
enough to augment ACT treatment in non-irradiated
animals consistent with findings that TBI provides mul-
tiple benefits to maximize ACT therapy, including TBI-
mediated removal of immune cells by suppressive donor
T cells. Moreover, beyond LPS, it is now well appreciated
that a variety of microbial components induced by
TBI/chemotherapy (or induced by other types of im-
munotherapies), can dramatically alter T cell-mediated
tumor regression. Thus, it is likely that multiple TLRs,
NODs, etc. on various innate immune cells are triggered,
thereby enhancing T cell-based immunotherapies.
Importantly, we found that LPS doses toxic to non-
irradiated mice were well tolerated in mice given low
dose irradiation (5Gy TBI), possibly due to the fact that
the number of APCs are reduced following irradiation
[32] and therefore are unable to respond to LPS therapy.
Furthermore, clinically available MPL and CpG-DNA
was safe in 5Gy TBI mice and mediated CD8+ T cell-
mediated destruction of tumors. Besides the difference
in CpG sequence specificity, one important distinction
between mice and humans is the expression pattern of
TLR9 on immune cells. In humans, TLR9 is expressed
only on pDC and B cells, whereas mice additionally ex-
press TLR9 on cells from the myeloid-lineage, resulting
in a more dynamic response. All other effects of TLR9
ligands on human immune cells seem to be indirect
and depend on factors produced by pDCs and B cells
[44–46]. These differences may alter the translatability
of CpG therapy (found in our work, Fig. 7b) between
mouse and human. None the less, our data suggest that
clinically available MPL, CpG, vaccines, or perhaps a
recombinant human OX40 ligand or CD40 ligand could
be used to safely activate the innate system [39, 47–49],
thereby enhancing the infused tumor-reactive lympho-
cytes [50, 51]. Indeed, the engagement of the innate im-
mune system as a trigger of the adaptive immune
system represents a powerful approach to enhance
adoptive immunotherapy. Moreover, it is likely that
these therapies alter the contents of the microbiome,
which many have recently published, have long-term
and often positive consequences of mainstream check-
point modulators [52, 53].
We found that administering LPS after a tripartite
ACT therapy could improve tumor regression in irradi-
ated (but not in non-irradiated) animals. However, add-
itional investigation revealed that we could obviate the
requirement for host preconditioning and drive curative
responses in non-irradiated animals if we antibody ab-
lated host CD4+ T cells transiently, along with ACT
treatment followed by TLR agonist therapy. In retro-
spect, these findings are not surprising, as LPS has been
shown to preferentially support the generation of regula-
tory T cells, known to suppress effector CD8+ T cells.
Although some helper CD4+ T cells are known to bolster
the cytotoxicity of CD8+ T cells, such as Th1 and Th17
cells, other non-specific CD4+ T cells impair the engraft-
ment of infused CD8+ T cells by competing for cytokines
induced by lymphopenia. Given that ablating CD4+ T
cells enhances the antitumor therapy of pmel-1 CD8+ T
cells, it would be interesting to execute these studies in
Foxp3DTR mice, eliminating FoxP3+ T regulatory cells.
Ongoing studies in our laboratory are now focused on
a
b
Fig. 8 Long-term curative responses can be mediated in mice without
lymphodepletion by depleting host CD4+ T cells and activating APCs
with TLR4 agonists LPS. (a) Scheme for treating non-irradiated mice
with CD4 depleting antibody, a tripartite ACT treatment and LPS.
(b) Tumor eradication via ACT can be achieved without host
preconditioning via antibody depleting CD4 lymphocytes that act
as Treg and cytokine sinks and activating innate immunity via TLR
signaling. One day before ACT, mice were antibody depleted of
host CD4+ T cells and subsequently administered every other day
for a total of 5 doses. The ACT treatment regimen was comprised
of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100
vaccination and hIL-2 or were left untreated. One day after ACT, mice
received 2 μg of LPS or were left untreated. Data shown (mean ± SEM,
5 mice per group) are representative of 4 independent experiments.
NT (black diamond) vs. PFI, PFI + LPS, or PFI + anti-CD4, *P < .05.
PFI + LPS + anti-CD4 (black circle) vs. all groups P < 0.001, ANOVA
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mechanistically understanding how this potent therapy
is modulating the immune system to cure large estab-
lished melanoma. We are also interested in understand-
ing how and what type of host CD4+ T cells are
reconstituting in these mice and if they are influencing
the generation and memory biology of tumor-specific
CD8+ T cells in vivo.
Finally, it is compelling to us that LPS could act either
to enhance or hinder therapy depending on when it was
delivered to the host. Though the LPS signal is meant to
enhance the donor CD8+ T cells, particularly in the case
of administering LPS before T cell infusion, it appears
that this beneficial signal bolsters the generation of host
immune cells over tumor specific T cells (Is this a
phenomenon restricted to ACT therapy or does it im-
pair vaccines, chemotherapy and/or checkpoint modula-
tors as well?). Moreover, we also found that giving LPS
during or prior to the tripartite regimen does not as ro-
bustly enhance the host DCs ability to drive the prolifer-
ation of the tumor-specific CD8+ T cells. In contrast, if
LPS was given after the tripartite regimen, the host DCs
effectively mediated the proliferation of pmel-1 CD8+ T
cells in vitro. Based on these findings, our data argue
that it is critical to consider when distinct therapies are
given to a patient, particularly given that many investiga-
tors, including ourselves, believe that the path forward
to improved treatment outcome in patients will be
through combinatorial therapeutic approaches [54–57].
Conclusion
Collectively, our results indicate that, though often over-
looked in the design of cancer immunotherapy based
clinical trials, that the temporal arrangement of
multiple-treatment delivery is a paramount consider-
ation in designing next generation T cell-based immuno-
therapies for cancer and infectious diseases. Specifically,
our data identify how and when to administer TLR ago-
nists to augment T cell-based immunotherapy in the ab-
sence or presence of host preconditioning.
Methods
Mice
To investigate the ability of TLR agonists to enhance
ACT, we used the pmel-1 model to target B16F10 mel-
anoma. All mice were bred and housed at NIH or
MUSC facilities. Female pmel-1 TCR transgenic mice
were crossed with C57BL/6-Ly5.1 Tg mice (C57BL/6-
pmel-1-Ly5.1 mice; Jackson Laboratory). C57BL/6 and
MyD88-/- (Taconic) were used as recipients in ACT ex-
periments. Experiments were conducted with the ap-
proval of the National Cancer Institue and Medical
University of South Carolina Animal Use and Care
Committee. The poorly immunogenic murine gp100+
B16F10 melanoma tumor was used.
In vitro activation of pmel-1 CD8+ T cell generation
Pmel-1 splenocytes were cultured in the presence of
1 μM hgp10025-33 (KVPRNQDWL) with culture media
containing 30 IU/ml of recombinant human IL-2 (rhIL-
2; NCI preclinical repository), as described elsewhere
[11]. Cells were transferred 7–10 days after the start of
the culture.
Regimen with adoptive transfer, vaccination, cytokines
and TLR agonists
Recipient 6–10 week old mice were injected subcutane-
ously with 5e5 of the poorly immunogenic B16F10
tumor cells. Eight days later, mice received 0.5-1e6 in
vitro activated pmel-1 CD8+ T cells. 5Gy TBI was given
to mice the morning of ACT. CD4+ T cells were de-
pleted by i.p. administration of 0.1 mg/mouse of anti-
CD4 antibodies (BD Biosciences) -1, 1, 3, 5 and 7 days
relative to cell transfer. Mice were vaccinated with 2e7
PFU of recombinant fowlpox virus expressing human
gp100 (Therion Biologics). rhIL-2 was administered at
36 μg/dose 2X/day for five doses. Ultra-pure LPS
(Invivogen; 0.1–50 μg, i.v.) was administered either
1 day pre, during or 1 day post PFI treatment. In
some experiments, MPL (5 μg, i.v.) was given on day
1 following ACT. Alternatively, CpG (5’-TCCAT-
GACGTTCCTGATGCT-3’) was given i.t. at 10 μg/
day for 4 consecutive days. Experiments conducted in
a randomized fashion and tumor measurements recorded
over time by individuals unaware of treatment groups.
Enumeration and phenotype of cells
At the indicated times, transferred pmel-1 cells were
enumerated by multiplying the percent of Ly5.1/CD8+ T
cells in the spleen by the absolute spleen count. Data
were acquired on a BD LSRII (BD Biosciences) and ana-
lyzed using FlowJo software (Tree Star, Ashland, OR).
Ex vivo proliferation assay
Untouched pmel-1 cells were isolated from splenocytes
of an untreated animal, CFSE-labeled, and co-cultured at
a 10:1 ratio with sorted CD11b+CD11chiCD86hi dendritic
cells from tumor-bearing mice (day 6 post-ACT) given
LPS at different time points. CFSE dilution was assayed
on days 0, 2 and 4 post activation.
Mucosal barrier score and detection of serum LPS
Colons were removed from mice and placed in 10 % for-
malin for 48 h, and then embedded in methylacrylate.
4–5 mm sections were taken along the papillary-optical
axis. Sections were evaluated by a pathologist unaware
of the identity of the groups using the scores as follows:
normal architecture = 0, some signs of edema = 1, mild
cell infiltration and reduction of crypts and goblets = 2,
severe cell infiltration and profound reduction of crypts
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and goblets = 3, severe cell infiltration and visually un-
detectable crypt and goblets = 4. An LAL assay (QCL-
1000; Cambrex) was used to analyze serum LPS on day 6.
BrdU incorporation
Three days after treatment, mice were injected i.p. with
1 mg of BrdU (Sigma-Aldrich, St. Louis, MO). After two
hours, the spleens from treatment groups were har-
vested, homogenized, and stained for pmel-1. Cells were
permeabilized using Cytofix/Cytoperm (Pharmingen),
treated with DNaseI (Sigma-Aldrich) for 1 h at 37 °C,
then stained with FITC-conjugated anti-BrdU (BD Bio-
sciences), and analyzed using FACS.
Additional files
Additional file 1: One day after TBI, mice received an ACT treatment
comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells,
fowlpox hgp100 vaccination and hIL-2 or were left untreated. Either
on day during or one day after ACT, mice received 2 μg of LPS or were
left untreated. Flow cytometry data shown are from splenocytes. (A)
Percentage of CD25highFOXP3 + CD4+ T cells on day 5 following PFI. (B)
Ratio of donor pmel-1 to host CD4+ T cells on day 5. ***P < .001**P < .01,
*P < .05, ANOVA. APCs were gated on either conventional DCs (C) or
monocytes (D) on day 2 following PFI. (PDF 255 kb)
Additional file 2: One day before ACT, mice were antibody depleted
of host CD4+ T cells (0.1 mg/treatment) and subsequently
administered every other day for a total of 5 doses or left
untreated. The ACT treatment regimen was comprised of the adoptive
transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination
and hIL-2 or were left untreated. One day after ACT, mice received
2 μg of LPS. The ratio of donor Vβ13 to host CD4 cells are shown from
splenocytes on day 5 (mean ± SEM, 5 mice per group). ****P < .0001,
unpaired t-test. (PDF 70 kb)
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HSC: Hematopoietic stem cell; LPS: Lipopolysaccharide;
MPL: Monophosphoryl lipid A; PFI: P = infusion of 1e6 pmel-1 CD8+ T cells,
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